Literature DB >> 22343226

The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention".

Christopher P Crum1, Frank D McKeon, Wa Xian.   

Abstract

A novel origin for pelvic serous cancer (ovarian cancer) has been proposed in the distal oviduct. This has important implications, including both early detection in high-risk women and wisdom of relying on serological tests to detect a disease that begins so close to the peritoneal surfaces. With the recent discovery of premalignant disturbances in gene function in the tubal mucosa, the concept of targeted prevention is emerging whereby the interruption of a portion of the carcinogenic pathway will prevent cancer. This alternative to detect early malignancy is a new paradigm in the quest to prevent this deadly disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22343226      PMCID: PMC3319355          DOI: 10.1097/GRF.0b013e31824b1725

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN: 0009-9201            Impact factor:   2.190


  51 in total

1.  Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.

Authors:  S M Domchek; M M Gaudet; J E Stopfer; M H Fleischaut; J Powers; N Kauff; K Offit; K L Nathanson; M Robson
Journal:  Breast Cancer Res Treat       Date:  2010-01       Impact factor: 4.872

2.  Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.

Authors:  Jason Madore; Fengge Ren; Ali Filali-Mouhim; Lilia Sanchez; Martin Köbel; Patricia N Tonin; David Huntsman; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  J Pathol       Date:  2010-02       Impact factor: 7.996

3.  Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria.

Authors:  Dana R Semmel; Ann K Folkins; Michelle S Hirsch; Marisa R Nucci; Christopher P Crum
Journal:  Mod Pathol       Date:  2009-05-01       Impact factor: 7.842

4.  Preventing future cancers by testing women with ovarian cancer for BRCA mutations.

Authors:  Janice S Kwon; Molly S Daniels; Charlotte C Sun; Karen H Lu
Journal:  J Clin Oncol       Date:  2009-10-19       Impact factor: 44.544

5.  Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol.

Authors:  Joseph T Rabban; Ellen Krasik; Lee-May Chen; Catherine B Powell; Beth Crawford; Charles J Zaloudek
Journal:  Am J Surg Pathol       Date:  2009-12       Impact factor: 6.394

6.  Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: frequency and potential significance.

Authors:  Elke A Jarboe; Alexander Miron; Joseph W Carlson; Michelle S Hirsch; David Kindelberger; George L Mutter; Christopher P Crum; Marisa R Nucci
Journal:  Int J Gynecol Pathol       Date:  2009-07       Impact factor: 2.762

7.  Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin?

Authors:  Michael H Roh; David Kindelberger; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2009-03       Impact factor: 6.394

8.  Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers.

Authors:  Patricia A Shaw; Marjan Rouzbahman; Ellen S Pizer; Melania Pintilie; Heather Begley
Journal:  Mod Pathol       Date:  2009-06-19       Impact factor: 7.842

9.  Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.

Authors:  Martin Köbel; Steve E Kalloger; Niki Boyd; Steven McKinney; Erika Mehl; Chana Palmer; Samuel Leung; Nathan J Bowen; Diana N Ionescu; Ashish Rajput; Leah M Prentice; Dianne Miller; Jennifer Santos; Kenneth Swenerton; C Blake Gilks; David Huntsman
Journal:  PLoS Med       Date:  2008-12-02       Impact factor: 11.069

10.  Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis.

Authors:  K Levanon; V Ng; H Y Piao; Yi Zhang; M C Chang; M H Roh; D W Kindelberger; M S Hirsch; C P Crum; J A Marto; R Drapkin
Journal:  Oncogene       Date:  2009-11-23       Impact factor: 9.867

View more
  38 in total

Review 1.  Research Needs for Understanding the Biology of Overdiagnosis in Cancer Screening.

Authors:  Sudhir Srivastava; Brian J Reid; Sharmistha Ghosh; Barnett S Kramer
Journal:  J Cell Physiol       Date:  2016-04-29       Impact factor: 6.384

Review 2.  Preclinical Models of Ovarian Cancer: Pathogenesis, Problems, and Implications for Prevention.

Authors:  Anthony N Karnezis; Kathleen R Cho
Journal:  Clin Obstet Gynecol       Date:  2017-12       Impact factor: 2.190

3.  New views on the pathogenesis of high-grade pelvic serous carcinoma with suggestions for advancing future research.

Authors:  Mark E Sherman; Richard Guido; Nicolas Wentzensen; Hannah P Yang; Phuong L Mai; Mark H Greene
Journal:  Gynecol Oncol       Date:  2012-08-29       Impact factor: 5.482

Review 4.  The role of the fallopian tube in the origin of ovarian cancer.

Authors:  Britt K Erickson; Michael G Conner; Charles N Landen
Journal:  Am J Obstet Gynecol       Date:  2013-04-10       Impact factor: 8.661

Review 5.  Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence.

Authors:  Mark E Sherman; Ronny I Drapkin; Neil S Horowitz; Christopher P Crum; Sue Friedman; Janice S Kwon; Douglas A Levine; Ie-Ming Shih; Donna Shoupe; Elizabeth M Swisher; Joan Walker; Britton Trabert; Mark H Greene; Goli Samimi; Sarah M Temkin; Lori M Minasian
Journal:  Cancer Prev Res (Phila)       Date:  2016-05-24

6.  Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers.

Authors:  Chang K Sung; Dawei Li; Erik Andrews; Ronny Drapkin; Thomas Benjamin
Journal:  Mol Oncol       Date:  2012-12-12       Impact factor: 6.603

7.  Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis.

Authors:  Yiying Wang; Li Li; Yue Wang; Sarah Ngocvi Tang; Wenxin Zheng
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

8.  Ovarian cancer screening effectiveness: A realization from the UK Collaborative Trial of Ovarian Cancer Screening.

Authors:  Edward J Pavlik
Journal:  Womens Health (Lond)       Date:  2016-09-05

9.  Advanced ovarian cancer: what should be the standard of care?

Authors:  Barbara A Goff
Journal:  J Gynecol Oncol       Date:  2013-01-08       Impact factor: 4.401

10.  Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis.

Authors:  Yiying Wang; Li Li; Yue Wang; Sarah Ngocvi Tang; Wenxin Zheng
Journal:  Am J Transl Res       Date:  2016-01-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.